CLINICAL_TRIALS
ClinicalTrials.gov record update
Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications Including Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/Phaeochromocytoma, Medullary Thyroid Carcinoma, and Repeat Peptide Receptor Radionuclide Therapy
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT06121271
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:25.586893+00:00
- Published At
- 2023-12-07T00:00:00+00:00
- Record Updated At
- 2023-12-07
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Bronchial and Thymic Neuroendocrine Tumour", "Paraganglioma/ Phaeochromocytoma", "Medullary Thyroid Carcinoma", "Those Requiring Repeat Peptide Receptor Radionuclide Therapy"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-12-07"- protocolSection.identificationModule.nctId
"NCT06121271"- protocolSection.identificationModule.officialTitle
"Trial of Lu-177 DOTATATE (Lutathera\u00ae) in Unlicensed Indications Including Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/Phaeochromocytoma, Medullary Thyroid Carcinoma, and Repeat Peptide Receptor Radionuclide Therapy"- protocolSection.statusModule.overallStatus
"NOT_YET_RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.